Baidu
map

Pharmacotherapy:治疗MRSA菌血症:达托霉素说明书剂量是理想选择?

2018-03-16 门鹏 环球医学网

发表在《Pharmacotherapy》的一项由美国科学家进行的研究考察了较高的达托霉素剂量(7mg/kg或更高)与耐甲氧西林金黄色葡萄球菌(MRSA)菌血症患者生存期改善的相关性。

发表在《Pharmacotherapy》的一项由美国科学家进行的研究考察了较高的达托霉素剂量(7mg/kg或更高)与耐甲氧西林金黄色葡萄球菌(MRSA)菌血症患者生存期改善的相关性。

研究目的:当前指南建议,对于耐甲氧西林MRSA菌血症患者,达托霉素的剂量要高于6mg/kg的说明书剂量,然而,支持该建议的证据来自于体外和病例系列研究。本研究比较了达托霉素说明书剂量vs较高的剂量在MRSA菌血症中的有效性。

设计:回顾性全国队列研究。

地点:退伍军人事务医疗中心。

患者:总共371例MRSA菌血症成人患者,这些患者于2002~2015年住院并在初始培养后的24小时内接受了初始万古霉素治疗,之后7天转换为达托霉素治疗。其中的138例(37.2%)接受了高于说明书的达托霉素剂量(7mg/kg或更高),233例(62.8%)接受了说明书剂量(6mg/kg)。

测量指标和主要结果:使用倾向得分匹配Cox成比例风险回归模型比较了说明书剂量和高于说明书剂量的患者的临床结局。为了鉴别与最佳生存相关的剂量分割,研究者使用了分类和回归树(CART)分析,并使用30天死亡率风险评分控制了混杂因素。较高剂量组和说明书剂量组的倾向得分匹配的30天死亡率分别为8.6%(6/70例)和18.6%(13/70例)(风险比[HR],0.31;95% 置信区间[CI],0.10~0.94)。组间院内死亡率、住院日、30天再入院、30天金黄色葡萄球菌再感染无显着差异。CART分析显示,7mg/kg或更高剂量的达托霉素仅在具有较高30天死亡预测概率(超过51%)的患者中具有获益(P<0.001)。

结论:据我们所知,这是第一项对MRSA菌血症患者的达托霉素剂量进行有效性比较的研究。高于达托霉素说明书剂量(7mg/kg或更高)在治疗MRSA菌血症上具有生存获益。这些数据表明,高于达托霉素说明书的剂量是改善MRSA菌血症患者临床结局的首选剂量。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]
    2018-11-18 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]
    2018-11-11 1237abe9m10暂无昵称

    超级棒

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]
    2018-10-28 jj000001
  8. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1996148, encodeId=edc0199614839, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 18 00:53:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908409, encodeId=f98f190840961, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 06 05:53:00 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352315, encodeId=7c10352315be, content=超级棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21fc2412052, createdName=1237abe9m10暂无昵称, createdTime=Sun Nov 11 22:10:43 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734636, encodeId=8b331e3463666, content=<a href='/topic/show?id=8ce91224840' target=_blank style='color:#2F92EE;'>#MRSA菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12248, encryptionId=8ce91224840, topicName=MRSA菌血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=056133789943, createdName=steven_u13, createdTime=Sat Jun 09 11:53:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054861, encodeId=2c592054861dd, content=<a href='/topic/show?id=250012241d8' target=_blank style='color:#2F92EE;'>#mRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12241, encryptionId=250012241d8, topicName=mRS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Jul 01 14:53:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738877, encodeId=39a91e38877ba, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Thu Jul 05 22:53:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787453, encodeId=ee6b1e87453e4, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Oct 28 12:53:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303943, encodeId=d44f1303943a6, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393742, encodeId=be441393e428b, content=<a href='/topic/show?id=ccc412243db' target=_blank style='color:#2F92EE;'>#MRSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12243, encryptionId=ccc412243db, topicName=MRSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507175, encodeId=64fe150e17567, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sun Mar 18 04:53:00 CST 2018, time=2018-03-18, status=1, ipAttribution=)]

相关资讯

JCEM:多毛症的治疗选择!

由此可见,在治疗多毛症上,含有雌激素-孕激素的OCP、抗雄激素和胰岛素增敏剂均优于安慰剂。

被脱发这个世界难题困扰的朋友们,你们可以挽回颜面了!

现在上个网,能看到年轻人最大的问题,不是找不到工作找不到对象,而是脱发。 据世界卫生组织数据显示,在中国,平均六个人当中就有一个人存在脱发症状,同时脱发现象还会出现低龄化趋势,中青年成了“脱发大军”的主力,而且60%的男性在25岁前就开始脱发,在30岁前开始脱发的比例近84%。对于一些男性来说,没有什么事是比在浴室镜子中看到自己发际线又后退了或头发又稀疏了更让他们感到担忧的了。 被脱发这个世界

人文关怀同样是一种治疗

受导师派遣,攻读医学人文硕士专业的医学生王子颖慧,再度回到本科实习的医院进行学习,对于医疗救治、医学意义有了新的观察和思考。对于她的这份成长与收获,身为导师的哈尔滨医科大学人文社会科学学院院长尹梅教授看在眼里、喜在心上。与其说,这是一个医学生向老师的实习汇报,不如说这是医学人文教育的生动呈现。——编者

JAMA:全新综述——甲状腺结节的诊断和治疗

最新一期(March 6,2018)的JAMA发表了一篇针对甲状腺结节诊疗的综述。该综述在PubMed和Scopus数据库中检索了过去3年来针对甲状腺结节评估和治疗的文献,关注甲状腺结节管理的重要临床问题。

医生,你会解释治疗风险吗?

床诊治过程中,患者知情同意是其中一个重要的环节。纵观国内外,很多医疗纠纷及诉讼案件其起因就是源于知情同意书或者操作没有解释到位(美国高达40%)。我们总是以为患者懂了,但其实他们很多情况并不能理解清楚。今天想和大家分享一些美国医生在解释风险治疗过程中的核心要素。值得一提的是,这些“人文课程”在美国医学院都有,课程围绕患者沟通进行多种维度的医学人文培训,后期还有模拟实训场景(诸如如何辨识家暴患者等)

妇科鼻祖傅青主,如何治疗月经先后不定期

导读:女性朋友每月都要悉心关照的月经状况,往往直接决定了自己的健康程度,但是您对经、带、胎、产这四大类妇科疾病有多少了解呢?什么叫月经先后不定期?我们该怎么理解月经先后不定期的发病机制呢?妇科鼻祖傅青主,为后人留下了关于月经先后不定期怎样宝贵的方子呢?祁老师为何如此推崇侠医傅青主?本讲话题中祁老师又会怎样为大家解读《傅青主女科》的片段章节呢?

Baidu
map
Baidu
map
Baidu
map